Matrine
vs Cancer
https://www.youtube.com/watch?v=Ya1PH7gIW-8
http://www.itmonline.org/arts/oxymatrine.htm
MATRINE
AND OXYMATRINE
Subjects
Of Chinese Research
by
Subhuti Dharmananda, Ph.D., Director, Institute for
Traditional Medicine, Portland, Oregon
Matrine and oxymatrine are the two major alkaloid components
found in sophora roots. They are obtained primarily from Sophora
japonica (kushen), but also from Sophora subprostrata
(shandougen), and from the above ground portion of Sophora
alopecuroides. The matrines were first isolated and identified
in 1958; they are unique tetracyclo-quinolizindine alkaloids
(see Figure 1) found only in Sophora species thus far. An
intensive investigation into the pharmacology and clinical
applications of these alkaloids has gone on for the past decade
and remains one of the focal points of Chinese medical research.
The main clinical applications are treatment of people with
cancer, viral hepatitis, cardiac diseases (such as viral
myocarditis), and skin diseases (such as psoriasis and eczema).
The crude herb and crude hot-water extracts of sophora have been
available in the West for more than 25 years. An alkaloid
fraction of sophora roots containing a standardized level of
oxymatrine and matrine (20%) was first introduced by the
Institute for Traditional Medicine, and made available to
practitioners in tablet form under the name Oxymatrine (White
Tiger) in 1998. It has been used without reported side effects.
In China, the alkaloids are often given by injection, but this
method of administration is not acceptable in the West, so oral
dosing is used here instead. When taken orally, much of the
oxymatrine is converted to matrine; to get high blood levels of
oxymatrine, it must be given by injection. However, it is
unclear whether oxymatrine is clinically more effective than
matrine. Chinese researchers have also used the alkaloids in
capsule form, with results that appear similar to the injection.
Sophora is also administered in complex formulas made as
decoctions and taken orally.
Sophora japonica contains about a dozen alkaloids, with matrine
and oxymatrine being by far the highest, together comprising
about 2% of the dried root stock (most of it in the form of
oxymatrine), followed by closely related alkaloids: mainly
sophocarpine, but also minute amounts of sophoranol,
sophoramine, sophoridine, allomatrine, isomatrine, and others
(see Figure 2). These alkaloids were first reported as
constituents of kushen in a series of publications from
1958-1978.
An overview of recent research on the pharmacology and clinical
applications of the sophora alkaloids is presented below. In
general, the dosage of the sophora alkaloids administered
clinically is in the range of 400-600 mg per day.
VIRAL
HEPATITIS
As described by Chen Yanxi and his colleagues at the Shanghai
Second Medical University (1):
In recent years, oxymatrine has been recommended for treating
chronic hepatitis B and chronic hepatitis C and has been shown
effective in clinical practice. It has been utilized for these
applications broadly, but the factors affecting its efficacy
have not yet been determined.
Chen and his group gave oxymatrine injection to patients with
hepatitis B. He confirmed that the viral load declined by this
treatment, suggesting that oxymatrine served to inhibit the
viral replication, not just reduce liver damage, which is the
primary and more limited effect of many herbs used for
hepatitis. Antiviral activity, for hepatitis C virus, was
confirmed by the same group in cell culture tests (2). Clinical
effectiveness for patients with hepatitis C had been reported
earlier, including reduction of viral load (3). Oxymatrine may
reduce death of liver cells damaged by means other than by
inhibiting viral activity, as indicated in a pharmacology study
of liver protective effects in immune-based liver damage (4).
Kang Junjie and Kang Suqiong, at the Treatment Center for
Hepatic Diseases of the Amoy Municipal Hospital, reported that
oxymatrine injection did not cause side effects other than rare
local reactions at the injection site (5). They used this
injection along with oral administration of complex Chinese herb
formulas designed to match symptom-sign complexes and claimed
that the effects were comparable to those attained with
interferon therapy, except that adverse reactions were avoided.
In particular, they claimed that the use of oxymatrine and
Chinese herb formulas inhibited liver fibrosis (for further
information on Chinese herbs for this purpose, see: Treatment
and prevention of liver fibrosis). The inhibition of fibrosis
appears to be a separate for additional function of sophora
alkaloids beyond inhibiting viral activity. In laboratory animal
studies carried out by Chen Weizhong and his colleagues at the
Changzheng Hospital in Shanghai, matrine was shown to reduce the
formation of liver fibrosis that was caused by chemical damage
to the liver (6).
Thus, in relation to viral hepatitis, the sophora alkaloids
appear to inhibit the viral replication, reduce destruction of
liver cells, and protect against fibrosis. It has also been
suggested that the alkaloids promote the flow of bile.
CANCER
Sophora subprostrata has long been regarded an anticancer herb
in China. According to cancer specialist Chang Minyi (7),
"Sophora subprostrata works through stimulating the anticancer
immune mechanism of the patient and reinforcing his resistance
against the growth of the tumor." In 1998, Xu Xiangru and Jiang
Jikai, working at the Congqing University of Medical Sciences,
published a review of anticancer activity of sophora alkaloids
(8). They relayed pharmacology studies indicating the alkaloids
could inhibit growth of tumor cells directly, and could also
affect immune functions. In clinical work, they described the
use of sophora alkaloids for treating the side effect of
leukopenia caused by cancer chemotherapy or radiation therapy
and for treating certain cancers, notably uterine cervical
cancer and leukemia. The herb is also considered an important
ingredient in treatment of esophageal and laryngeal cancer. In a
recent pharmacology study, it was reported that matrine could
help leukemia cells differentiate into mature and normal white
blood cells (9). Nonetheless, sophora alkaloids should not be
relied upon as a sole treatment for cancer, but as an adjunct
therapy, as there is no proof that the herb or these compounds
are curative.
CARDIAC
DISEASES
Sophora and its alkaloids are commonly used in China for
treatment of heart arrhythmias (10). A possible mechanism of
action is to help block sodium and calcium channels, a mechanism
relied on by several antiarrhythmic pharmaceuticals. In a review
of sophora alkaloid effects on the heart, Li Yan and He Liren,
at the Affiliated Yueyang Hospital of Shanghai University of
TCM, reported that:
sophora total alkaloids or matrine could
counteract arrhythmia induced by many causes;
the total alkaloids or oxymatrine could
regulate heart contractility;
the total alkaloids could dilate the coronary
artery, increase blood flow, and improve oxygen delivery to
cardiac cells; and
sophora root could counteract the coxsackie
virus that causes myocarditis.
Li and He also relayed a clinical report from the Third Clinical
Medical College of Beijing Medical University, about treatment
of 167 patients with fast arrhythmia. The patients received each
day 3-10 sophora root tablets (extract of 2 grams crude
herb/tablet). The results indicated positive effects on various
kinds of arrhythmia, such as premature systole, paroxysmal
ventricular tachycardia, atrial fibrillation, and sinus
tachycardia; the efficacy for premature systole appeared to be
the best. This Beijing study and others were described also by
Niu Kuizhi in his review (12) of clinical applications of
sophora (kushen).
SKIN
DISEASES
Sophora is frequently used in treatment of skin diseases,
applied topically and consumed orally. One of the primary uses
for topical therapy is treatment of vaginitis, particularly that
due to candida infection (13). Recently, a topical liniment was
developed combining sophora's matrine with the anti-inflammatory
flavonoid baicalin from scute (huangqin) for treatment of
eczema, neurodermatitis, and psoriasis (14). This treatment was
reported to be highly effective, especially for eczema, though
the number of cases was small, so that further research must be
done. The use of sophora for psoriasis is a promising new area
(15). Zhang Junling and his colleagues at the Department of
Dermatology, Tianjin Changzheng Hospital, studied the mechanism
by which sophora alkaloids reduce psoriasis patches (16). They
found that the alkaloids could inhibit keratinocytes, the cells
that reproduce continuously to produce the characteristic
scales.
Matrine

Oxymatrine

REFERENCES
Chen Yanxi, et al., Relationship between
serum load of HBV-DNA and therapeutic effect of oxymatrine in
patients with chronic hepatitis B, Chinese Journal of Integrated
Traditional Chinese and Western Medicine 2002; 22 (5): 335-336.
Chen YX, et al., The inhibitory effect of
oxymatrine on hepatitis C virus in vitro, Chinese Journal of
Liver Diseases 2001; 9 (Supplement): 12-14.
Li Jiqiang, et al., A preliminary study on
therapeutic effect of oxymatrine in treating patients with
chronic hepatitis C, Chinese Journal of Integrated Traditional
and Western Medicine, 1998; 18(4): 227-229.
Xiang X, et al., Effect of oxymatrine on
murine fulminant hepatitis and hepatocye apoptosis, Chinese
Journal of Medicine, 2002; 115(4); 593-596.
Kang Junjie and Kang Suqiong, 30 cases of
chronic hepatitis B treated with oxymatrine injection combined
with syndrome differentiation of Traditional Chinese Medicine,
Journal of Traditional Chinese Medicine, 2002; 43(1): 53.
Chen Weizhong, et al., Effect of matrine on
experiment rat liver fibrosis, Chin Journal of New Drugs, 2000;
19(5): 410-412.
Chang Minyi, Anticancer Medicinal Herbs, 1992
Hunan Science and Technology Publishing House, Changsha.
Xu Xiangru and Jiang Jikai, Recent progress
in anticancer bioactivity study of Sophora flavescens and its
alkaloids, Chinese Journal of Integrated Traditional Chinese and
Western Medicine 1998; 4 (3): 235-239.
Zhu Ningxi, et al., Study on inducing and
differentiating function and mechanism of matrine on leukemia
cells, ACTA Traditional Chinese Medicine and Pharmacology
(Shanghai), 2001; 15(1): 43-44.
Ding Guangsheng, Anti-arrhythmia agents in
traditional Chinese medicines, Abstracts of Chinese Medicine
1987; 1(2): 287-308.
Li Yan and He Liren, Pharmacological study of
Sophora alkaloid actions on the cardiovascular system, Chinese
Traditional and Herbal Drugs, 2000; 31(3): 227-229.
Niu Kuizhi, Pharmacology and clinical
application of sophora flavescentis, International Journal of
Oriental Medicine 1997; 22(1): 75-81.
Li Xiuying, et al., Treatment of 50 patients
with candida albicans vaginitis by cortex sophorae, Chinese
Journal of Integrated Traditional Chinese and Western Medicine
2000; 6 (2): 146-147.
Ding Ting, et al., The preparing and clinical
applications of Complex Matrine Liniment, ACTA Chinese Medicine
and Pharmacology, 2002; 30(2): 47-48.
Zhang Yaolong, Clinical study on matrine for
the treatment of psoriasis, Hebei Journal of Medical Science,
1996; 69 (2): 590-591.
Zhang Junling, et al., Study on Apoptosis
induced by oxymatrine in cultured keratinocytes, Chinese Journal
of Dermatology and Venereology, 2000; 14(6): 367-368.
http://www.ncbi.nlm.nih.gov/pubmed/21061465
PMID:21061465
DOI:10.1142/S0192415X10008512
Am J Chin Med. 2010;38(6):1115-30.
Therapeutic
effects of matrine on primary and metastatic breast
cancer.
Li H, Tan
G, Jiang X, Qiao H, Pan S, Jiang H, Kanwar JR, Sun X.
Abstract
Matrine, one of the main components extracted from a traditional
Chinese herb, Sophora flavescens Ait, has displayed anti-cancer
activity in several types of cancer cells. This study aims to
evaluate the therapeutic benefits of matrine on primary and
metastatic breast cancer. Matrine inhibited the viability of and
induced apoptosis in human MCF-7 and mouse 4T1 breast cancer
cells in a dose-dependent manner in vitro as shown by MTT assay,
flow cytometry and laser scanning confocal microscopy.
Administration of matrine inhibited the growth of primary tumors
and their metastases to lungs and livers, in a dose-dependent
manner, in a highly metastatic model of 4T1 breast cancer
established in syngeneic Balb/c mice. Tumors from
matrine-treated mice had a smaller proliferation index, shown by
immunostaining with an anti-Ki-67 antibody, a greater apoptosis
index, shown by TUNEL-staining, and a less microvessel density,
shown by immunostaining with an anti-CD31 A antibody, compared
to the controls. Western blot analysis of tumoral homogenates
indicated that matrine therapy reduced the ratio of Bcl-2/Bax,
downregulated the expressions of VEGF and VEGFR-2, and increased
the activation of caspase-3 and caspase-9. This study suggests
matrine may be a potent agent, from a natural resource, for
treating metastatic breast cancer because of its anti-apoptotic,
anti-proliferative and anti-angiogenic activities.
http://www.ncbi.nlm.nih.gov/pubmed/20930385
Biol Pharm Bull. 2010;33(10):1740-5.
Matrine
inhibits proliferation and induces apoptosis of pancreatic
cancer cells in vitro and in vivo.
Liu T1,
Song Y, Chen H, Pan S, Sun X.
Abstract
Matrine, an alkaloid extracted from a Chinese herb, Sophora
flavescens AIT., has exhibited anti-proliferative and
pro-apoptotic abilities against various types of cancer cells.
This study aims to investigate its anti-cancer activity and
underlying mechanisms in human pancreatic cancer cells in vitro
and in vivo. Human BxPC-3 and PANC-1 pancreatic cancer cells,
and human HL-7702 liver cells were incubated with matrine at
different concentrations. Cell viability was assessed by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay, and cell apoptosis, by flow cytometry. Subcutaneous
BxPC-3 xenograft tumors were established in nude BALB/c mice,
and matrine was intraperitoneally (i.p.) administered. The
tumors were monitored and harvested. Tumor sections were
immunostained with an anti-Ki-67 antibody (Ab) to examine cell
proliferation, or stained with terminal deoxynucleotidyl
transferase mediated deoxyuridine triphosphate (dUTP) nick-end
labeling (TUNEL) to evaluate in situ cell apoptosis. The
expression of proliferating cell nuclear antigen (PCNA) and
several apoptosis-related proteins in cells and tumor tissues
were evaluated by Western blot analysis. In in vitro assays,
matrine inhibited cell viability by downregulating the
expression of PCNA, and induced cell apoptosis by reducing the
ratio of Bcl-2/Bax, upregulating Fas, and increasing activation
of caspases-8,-3 and -9, in a dose-dependent manner.
Administration of matrine inhibited tumor growth in a
dose-dependent manner, and regulated tumoral gene expression
consistent with the in vitro results. But matrine had no
significant effects on the viability of HL-7702 cells or the
bodyweight of mice compared to controls. These results indicate
matrine may be a potential and promising agent of natural
resource to treat pancreatic cancer.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713592/
Int J Clin Exp Pathol. 2015; 8(11): 14793–14799.
http://www.ncbi.nlm.nih.gov/pubmed/26823806
Int J Clin Exp Pathol. 2015 Nov 1;8(11):14793-9
Matrine
inhibited proliferation and increased apoptosis in human
breast cancer MCF-7 cells via upregulation of Bax and
downregulation of Bcl-2.
Li H, Li
X, Bai M, Suo Y, Zhang G, Cao X.
Abstract
PURPOSE:
The aim of the present study was to investigate the effects of
matrine on proliferation and apoptosis in human breast cancer
MCF-7 cells and its relevant molecular mechanisms.
METHODS:
Breast carcinoma cell line MCF-7 was cultured with series
concentrations of Matrine in vitro. The proliferation and
apoptosis of MCF-7 cells were investigated by 3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
assay, flow cytometry, and Mitochondrial membrane potential
(MMP) measurements. The expression levels of Bax and Bcl-2
proteins were detected by Annexin V/propidium iodide coupled
staining. The morphological changes of MCF-7 cell were examined.
RESULTS:
The inhibition rates of MCF-7 cells were 6.01%-37.01%,
7.56%-53.92%, and 10.86%-70.23% for 24, 48, and 72 hours after
Matrine treatment, respectively. The proliferation of MCF-7
cells was significantly inhibited by Matrine administration,
with a time and dose dependent manner. The rates apoptotic cells
was between 4.17±0.25% and 19.63±0.17% in 0.25-2.0 mg/ml Matrine
groups, which had significant increased compare with the control
groups (1.10±0.08%, P<0.05). Meanwhile, increased Bax
expression, but decreased Bcl-2 expression was observed in MCF-7
cell line. MMP were significantly decreased by Matrine
treatment.
CONCLUSIONS:
Matrine significantly inhibited the growth and induced apoptosis
in breast carcinoma MCF-7 cells, which is related to Bax, Bcl-2
signaling and MMP.
Patents
Anti-cancer Chinese traditional patent medicine and
production method thereof
CN105250888
The invention relates to an anti-cancer Chinese traditional
patent medicine, which is obtained by processing Chinese herbs.
The anti-cancer Chinese traditional patent medicine is
characterized in that the product mainly contains steroidal
saponin, volatile oil, colchicine, matrine and puerarin, the
traditional Chinese medicine smilax glabra roxb is adopted as
the main raw material to prepare the product, and the
pharmaceutically acceptable dosage form or carrier is used.
Method for
analysis of matrine inhibited human pancreatic cancer cell
migration
CN104975064
The present invention discloses a method for analysis of matrine
inhibited human pancreatic cancer cell migration. The method
comprises the steps of: human pancreatic cancer cell culture,
single cell migration analysis, cell infiltration analysis,
ELISA adsorption analysis and immunoblotting analysis. Analysis
by using the method demonstrates that action by matrine for a
certain time can significantly reduce the migration and invasion
ability of human pancreatic cancer cells, and the expression of
human pancreatic cancer cell migration-related proteins, MT1-MMP
and Wnt, beta-Catenin is significantly decreased. Further
detection finds that MT1-MMP transcriptional activity is also
significantly reduced, which is consistent with the Wnt
signaling pathway activity; the matrine reduces the
transcription and expression of MT1-MMP by regulating Wnt
pathway activity, thereby further inhibiting migration and
infiltration of pancreatic cancer cells.
Preparing
method of matrine nanoparticles modified by wheat germ
agglutinin and application of matrine nanoparticles
CN104940142
The invention relates to a preparing method of matrine
nanoparticles modified by wheat germ agglutinin and application
of the matrine nanoparticles. The method and application
effectively solve the problems that preparing of the matrine
nanoparticles modified by the wheat germ agglutinin and matrine
are low in targeting and poor in using effect. According to the
matrine nanoparticles modified by the wheat germ agglutinin, the
matrine nanoparticles are connected with wheat germ agglutinin
through chemical bonds, and matrine is dissolved into a water
solution through water bath; polylactic acid-hydroxyacetic acid
copolymer acetone is dissolved into an organic phase through
water bath; the matrine water solution is dripped into the
organic phase to form colostrums, the colostrums is injected
into a polyving akohol water solution, acetone is volatilized,
centrifugation is conducted, sediment and drying are conducted,
and matrine nanoparticles are obtained; the matrine
nanoparticles are dissolved through a PBS solution, carbodiimide
and N-hydroxy succinimide is added, activation and
centrifugation are conducted, supernate is added into a solution
containing wheat germ agglutinin, incubation and centrifugation
are conducted, sediment and drying are conducted, and the final
matrine nanoparticles is prepared. According to the preparing
method, the preparation condition is met easily, the raw
material source is rich, the cost is low, and the preparing
method is innovation of cancer therapeutic drug.
Matrine
containing composition for treatment or prevention of mammal
cancer and other diseases
CN104887834
The invention discloses a matrine containing composition for
treatment or prevention of mammal cancer and other diseases. The
composition includes matrine and other plant extract. The other
plant extract can be at least one of a black bean peel extract,
a Vaccinium vitis-idaea extract, ginsenoside, alpha-linolenic
acid, a green tea extract, solanesol, coenzyme Q10, Hedyotis
diffusa, astragalus, Isatis tinctoria, Chinese angelica, Salvia
Miltiorrhiza, fructus ligustri lucidi, 5-hydroxytryptophan,
resveratrol, and Ginkgo biloba extract. In the way, by
cooperating matrine with the other plant extract, by cooperating
the drug effect of matrine with the effective medicinal
components of the other plant extract, the composition can be
used for conservative treatment or adjuvant treatment of various
cancers, prevention and treatment drugs for emergent infectious
diseases, or people that usually have low immunity and are
likely to get sick, and health preservation.
Application
of matrine compounds in preparing anti-hepatic fibrosis and
anti-liver cancer medicament
CN103933038
The invention relates to application of compounds and salt
thereof, and particularly relates to application of matrine
compounds and salt thereof in preparation of anti-hepatic
fibrosis and anti-liver cancer medicaments. The compounds have
the advantages of remarkably inhibiting the proliferation of
hepatoma cell lines Hep-G2, Hun-7, MHCC-97L, SMMC-7721 and
Hep-3B and proliferation activities of fibroblast BJ, human
hepatic stellate cells LX-2 and hepatic stellate cells HSC-T6,
and can be used for preparing medicaments for treating hepatic
fibrosis and liver cancer.
Matrine
derivative, its preparation method and application
CN102786522
The invention discloses of a matrine derivative with good
anti-inflammatory activity and its preparation method. The
matrine derivative has anti-inflammatory activity comparable to
that of matrine, and some derivative even reach the level of
dexamethasone. Thus, the matrine derivative provides a new
treatment choice for the vast number of cancer patients, and
also provides a good reference for utilization and
transformation of the active ingredients of natural products.
Application
of compounds inhibiting cell cycle progression in preparation
of drug inhibiting or removing double minute chromosomes in
tumor cells
CN102755345
The invention provides an application of compounds inhibiting
cell cycle progression in preparation of a drug inhibiting or
removing double minute chromosomes in tumor cells, and belongs
to the technical field of cancer biotherapy. Aiming at tumor
cells containing double minute chromosomes, the drug selects
compounds inhibiting cell cycle progression, like gemcitabine,
camptothecin, matrine and taxol, to perform low-concentration
action with the dose being thousands of times as low as the dose
of hydroxyurea in control group; and the result shows that
gemcitabine, camptothecin, matrine and taxol can reduce the
number of double minute chromosomes in cells and reduce
proliferation of cells carrying cancer genes, and further
effectively reduce malignancy degree of tumor cells containing
double minute chromosomes. The drug provided by the invention
improves specificity of treatment of malignant tumor, is
improved on the present therapeutic scheme, and has guidance
significance on clinical therapy.
Pharmaceutical
composition for treating colorectal cancer
CN102688240
The invention discloses a pharmaceutical composition for
treating colorectal cancer. The composition comprises
sophoridine, matrine, oxymatrine, aloperine, sophocarpine, etc.
The pharmaceutical composition has definite effect in inhibiting
cancer cells, and has the advantages of clear ingredients,
controllable quality, low toxicity, fast metabolism, and
significant effect in treating intestinal malignant tumors,
especially colorectal cancer.
Medicinal
composition with anti-tumor effect and application thereof
CN101822770
The invention discloses a medicinal composition with anti-tumor
effect and application thereof. The medicinal composition uses
kuh-seng alkaloid and rhizoma hterosmilacis as raw materials,
and effective ingredients of the raw materials comprise matrine,
oxidized matrine, sophocarpine, oxidized sophocarpine and
rhizoma hterosmilacis glycoside and the like. Pharmacodynamical
experiments show that the medicinal composition can be used for
resisting tumor and relieving cancer swelling pain, has synergy
and detoxification effects on tumor chemotherapy medicaments and
effects of improving the immunity and improving the quality of
life for cancer patients, and can be used for treatment of
hepatitis resistance and liver fibrosis.
Medicine
composition containing silymarin and kurainone or matrine and
use thereof
CN101357129
The invention relates to the medicine field, in particular to a
compound medicine combination which contains silybin and
oxymatrine or matrine and the application of the combination for
curing liver diseases, and more particularly relates to the
application for curing diseases such as hepatitis, liver damage
and liver cancer.
Composition
and its use as effective constituent of a medicine having
anti-angiogenesis synergy effect
US2008108642
The present invention relates to a composition as effective
constituent of a medicine having anti-angiogenesis synergy
effect and belongs to the field of medicine compositions. The
recipe is composed of matrine and sinomenine hydrochloride with
a content ratio of matrine:sinomenine hydrochloride=1:0.05 to 1.
The recipe of the present invention has synergic actions of
efficacy enhancing and toxicity reducing, has obvious therapy
effect to angiogenesis-related diseases such as rheumatoid
arthritis and cancer, has clear base of medicine effective
substance, and maintain the characteristic of traditional
Chinese medicine of recipe association.
Process for
the manufacture of a herbal composition
US2004170704
The present invention is concerned with a process for the
manufacture of a herbal composition, said process comprising: a.
subjecting a matrine containing plant material, in the absence
of a plant material derived from the species Dictamnus, to an
extraction with an aqueous solvent, optionally followed by a
concentration step, to produce a herbal extract I; b. subjecting
a plant material derived from the species Dictamnus, to an
extraction with an aqueous solvent, optionally followed by a
concentration step, to produce a herbal extract II; c. mixing
the herbal extracts I and II; d. provided the resulting mixture
contains a significant amount of water, drying the mixture to a
water content of less than 6 wt. %. The herbal composition
according to the present invention may advantageously be used in
a method of treating or preventing cancer, H. pylori infections,
chronic inflammatory conditions, cardiovascular diseases or
cerebral vascular diseases in mammals.
Safe
medicine for treating and preventing cancer and method of use
US2007166415
The present invention provides a new method for extracting
Homoharringtonine (HHT) by culture cells or culture plant
tissues. Also, disclosed are methods of obtaining HHT from
semi-synthesis and biosynthesis. The present invention disclosed
that HHT combined with some botanical drugs could induce cancer
cells to resemble normal cells. To add some botanical drugs
combined with HHT can significantly increase anticancer effects
of HHT. These drugs include Matrine (MAT), Guanzhongsu (GU),
Maidongsu (MU), and Indirubin (IND). The experimental data
showed that above drugs have strong synergisms effects for
treating leukemia and other cancer cells and more safe.
Safe
natural pharmaceutical composition for treating cancer
US2004072790
The present invention related to the natural drug of
Homoharringtonine (HHT) combined with other ingredients which
include Matrine (MAT), Apigenin (APN), Yejuhua lactone (YLE),
Lipopolysaccharide of Kelp (LIK), Puerarin (PUN) and Indirubin
(IND) for diverting human cancer cells to closely normal cells,
inducing apoptosis of cancer cells and inhibiting cancer cells.
Specifically, this invention provides a new method for producing
HHT and other ingredients
Safe
pharmaceutical composition for treating and preventing cancer
and method of use
US2007059385
The present invention provides a new method for extracting
Homoharringtonine (HHT) by culture cells or culture plant
tissues. Also, disclosed are methods of obtaining HHT from
semi-synthesis and biosynthesis. The present invention disclosed
that HHT combined with some botanical drugs could induce cancer
cells to resemble normal cells. To add some botanical drugs
combined with HHT can significantly increase anticancer effects
of HHT. These drugs include Matrine (MAT), Guanzhongsu (GU),
Maidongsu (MU), and Indirubin (IND). The experimental data
showed that above drugs have strong synergisms effects for
treating leukemia and other cancer cells and more safe.
Prepn.
method of matrine magnetic micro-ball
CN100362984
A process for preparing the magnetic matrine micro-ball used to
treat liver cancer includes such steps as proportionally mixing
FeCl3 with FeCl2, adding distilled water and NaOH solution or
ammonia water until pH=8, adding oleic acid and HCl or HAC until
pH=7 to obtain magnetic fluid, using acetic acid to prepare
chitosan solution, using distilled water to prepare
polyphosphate, proportionally mixing magnetic fluid, chitosan
solution and matrine, adding polyphosphate, stirring, separation
and drying. It has magnetic location and slow release functions.
Pure
Chinese medicine compound preparation for preventing and
treating cancer and malignant tumor
CN1682864
The compound Chinese medicine preparation for preventing and
treating cancer is compounded with ginseng, astragalus root and
matrine in certain proportion. The preparation process includes
decocting astragalus root, filtering and decompression
concentrating; alcohol solution reflux extraction of ginseng and
concentration; merging extracted solution, regulating pH value,
sterilizing, cold storing, suction filtering, and adding matrine
dissolved in injection water to obtain the medicine liquid. The
medicine liquid may be prepared into various forms, including
injection, transfusion fluid, powder for injection, tablet,
capsule, etc. The present invention can raise the immunity of
cancer patient and inhibit tumor.
Medicinal
composition for treating liver disease
CN1562055
A composite medicine for treating hepatitis, hepatofibrosis,
heptocirrhosis, hepatoascites and liver cancer is proportionally
compound of arasaponin and the kuhseng alkaloid chosen from the
common alkaloid of kuhseng, common alkaloid of subprostrate
sophora, common alkaloid of sophora alopecuroids, matrine and
kurannol.
http://www.missouribotanicalgarden.org/PlantFinder/PlantFinderDetails.aspx?kempercode=c149
Sophora
Japonica
Common Name: Japanese
pagoda tree
Type: Tree
Family: Fabaceae
Native Range: China, Korea
Zone: 4 to 8
Height: 50.00 to 75.00 feet
Spread: 50.00 to 75.00 feet
Bloom Time: July to August
Bloom Description: Creamy white
Sun: Full sun to part shade
Water: Medium
Maintenance: Low
Suggested Use: Shade Tree, Street Tree
Flower: Showy
Fruit: Showy
Tolerate: Drought, Air Pollution

Culture
Best grown in rich, medium moisture, well-drained sandy loams in
full sun to part shade. Best in full sun. Tolerant of common
city pollutants and conditions. Once established, it is also
tolerant of heat and some drought. Newly planted saplings may
not flower for as long as the first 10 years.
Noteworthy Characteristics
Japanese pagoda tree is native to China and Korea, but not
Japan. It is a medium to large deciduous tree that typically
matures to 50-75’ (less frequently to 100’) tall with a broad
rounded crown. It is generally cultivated for its attractive
compound foliage and fragrant late summer flowers. Pinnate
leaves (to 10” long), each with 7-17 oval, lustrous, dark green
leaflets, remain attractive throughout the growing season.
Leaves retain green color late into fall, resulting in no fall
color or at best an undistinguished greenish yellow. Small,
fragrant, pea-like, creamy white flowers (each 1/2” long) bloom
in late summer in sweeping terminal panicles to 12” long and to
12” wide. Flowers fall to the ground around the tree after bloom
covering the ground with a blanket of white. Flowers give way to
slender, 1- to 6-seeded, knobby, bean-like pods (to 3-8” long)
that mature to brown in fall and persist into winter. Although
not native to Japan, the specific epithet and common name seem
to recognize the early use of the tree in Japan around Buddhist
temples. This tree is also commonly known as Chinese scholar
tree.
Problems
No serious insect or disease problems. Twig blight, verticillium
wilt, canker, powdery mildew and rust may occur. Watch for leaf
hoppers.